Physician profile
Nancy I Faller
NPI 1811952740
$3,846.17
in general payments reported to CMS, 2019-2025
28 companies · $360 in 2025
The $360 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2020: $706 · 2021: $520 · 2022: $672 · 2023: $483 · 2024: $351 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,194.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $920.05 | 2019-2024 | Relistor |
| Abbott Laboratories | $703.15 | 2019-2025 | Eterna, Proclaim |
| Collegium Pharmaceutical, INC. | $506.31 | 2019-2025 | Belbuca |
| Boston Scientific Corporation | $301.19 | 2019-2025 | General - Therapies |
| Nevro Corp. | $190.11 | 2019-2024 | Senza |
| Biodelivery Sciences International, INC. | $126.74 | 2019-2021 | |
| Grt US Holding, INC. | $104.45 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $97.61 | 2024-2025 | |
| Daiichi Sankyo INC. | $87.02 | 2019 | |
| Assertio Therapeutics, INC. | $76.66 | 2019-2020 | |
| Redhill Biopharma INC. | $72.20 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $65.15 | 2021 | |
| Virtus Pharmaceuticals LLC | $64.53 | 2024-2025 | Levorphanol Tartrate |
| Scilex Pharmaceuticals INC. | $63.49 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $62.32 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $60.70 | 2019 | |
| Medtronic, INC. | $52.46 | 2023-2024 | Intellis Adaptivestim |
| Abbvie INC. | $48.97 | 2022 | |
| Pfizer INC. | $44.56 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.41 | 2022 | |
| Globus Medical, INC. | $29.35 | 2025 | Senza |
| Shionogi INC | $29.07 | 2019 | |
| Kaleo, INC. | $26.14 | 2019 | |
| Forte Bio-Pharma LLC | $25.55 | 2019-2020 | |
| Amgen INC. | $15.55 | 2019 | |
| Zyla Life Sciences, INC. | $13.95 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.40 | 2019 | |
| Ibsa Pharma INC. | $11.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Faller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.